Tesamorelin vs SLU-PP-332
Head-to-head comparison of Tesamorelin and SLU-PP-332 for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Tesamorelin | Slu Pp 332 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Experimental Exercise Mimetic |
| Mechanism | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. | SLU-PP-332 binds and activates all three estrogen-related receptors (ERRs), which are orphan nuclear receptors that serve as master transcriptional regulators of energy metabolism. |
| Evidence Rating | A — FDA Approved | D — Animal/Preclinical Only |
| Clinical Status | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy | Preclinical only. Published murine studies from Washington University. No human trials planned or initiated. |
| Safety Profile | Headache, nausea, and flu-like symptoms reported; May increase blood glucose -- monitoring recommended in diabetics | CRITICAL: No human safety data exists; All safety information derived from mouse studies only |
| Molecular Weight | ~5135.9 g/mol | N/A |
| Half-Life | ~26–38 minutes | Unknown in humans (short in mice, necessitating twice-daily dosing) |
Overview
Tesamorelin and SLU-PP-332 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Tesamorelin — Mechanism & Evidence
It stimulates endogenous GH and IGF-1 production. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.
Key claims: Reduces visceral adipose tissue in HIV lipodystrophy; Increases skeletal muscle area and density; Effective on INSTI-based HIV regimens.
Tesamorelin 10mg
10mg
SLU-PP-332 — Mechanism & Evidence
SLU-PP-332 is a small-molecule pan-agonist of estrogen-related receptors (ERRalpha, ERRbeta, ERRgamma) developed at Washington University in St. Louis. It activates the aerobic exercise gene program, increasing oxidative muscle fiber content, mitochondrial respiration, and exercise capacity in mice without training. It represents a fundamentally different approach from AICAR (AMPK activation) by targeting the transcriptional master regulators of oxidative metabolism. CRITICAL: No human trials exist; all data is from murine studies only.
Key claims: Increases exercise endurance without training; Shifts muscle fiber type toward oxidative phenotype; Protects against muscular dystrophy in mice.
Shared Research Applications
Both peptides are studied for: Body Composition.
Tesamorelin is also researched for: no additional unique applications.
SLU-PP-332 is also researched for: Metabolic Health.
Safety Considerations
Tesamorelin: Headache, nausea, and flu-like symptoms reported May increase blood glucose -- monitoring recommended in diabetics FDA pregnancy category X -- tesamorelin can harm an unborn baby or cause birth defects
SLU-PP-332: CRITICAL: No human safety data exists All safety information derived from mouse studies only Mice tolerated twice-daily dosing without reported toxicity
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.
Tesamorelin Research Interest Grows Among Synthetic GHRPs
Synthetic growth hormone-releasing peptides (GHRPs) are drawing increasing attention in scientific research, with tesamorelin emerging as a focal point. The compound, a synthetic analog of growth hormone-releasing hormone, is being studied for its potential to modulate growth hormone levels. This article examines the rising research interest in tesamorelin and its place within the broader class of synthetic GHRPs.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe